Results 181 to 190 of about 8,405,379 (306)

Long-term outcome in corneal endotheliitis with molecular detection of herpes simplex virus 1 and human herpes virus 6: a case report. [PDF]

open access: yesBMC Ophthalmol, 2022
Ono T   +7 more
europepmc   +1 more source

Scalp Dysesthesia: Emerging Pathophysiologic Insights and Therapeutic Implications

open access: yesInternational Journal of Dermatology, EarlyView.
Scalp dysesthesia is a chronic condition diagnosed through exclusion. This scoping review synthesized data from 59 patients to identify recurrent clinical features, comorbidities, and management strategies that may support earlier diagnosis. Emerging patterns suggest that neuronal sensitization may underlie common symptoms.
Aditya K. Gupta   +4 more
wiley   +1 more source

The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma

open access: yesImmunology &Cell Biology, EarlyView.
(Left)The identification and elimination of tumour cells is enabled by the infiltration of functional innate and adaptive immune effectors into the TME, such as natural killer cells (NK cells) and cytotoxic T cells (CD8 T cells). Effective innate and adaptive immune responses facilitate immunological control of malignant outgrowth.
Sarah J. MacDonald   +6 more
wiley   +1 more source

Unmasking the Influence of Viral Micro‐RNAs on Host Immunity

open access: yesImmunology &Cell Biology, EarlyView.
Viral micro‐RNAs are increasingly recognized as key modulators of host–virus interactions. They influence multiple immune functions, including antigen presentation, T‐cell activation, and cytokine signaling, while also tuning viral gene expression to promote persistence.
Riley J. K. Easton   +1 more
wiley   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy